Search company, investor...

Predict your next investment

Debt & Specialty Finance
FINANCE | Lending
horizontechfinance.com

Investments

124

Portfolio Exits

50

Partners & Customers

2

Service Providers

1

About Horizon Technology Finance

Horizon Technology Finance (NASDAQ: HRZN) is a business development company specializing in lending and and investing in development-stage investments. It focuses on making secured debt and venture lending investments to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries. It seeks to invest in companies in the United States.

Headquarters Location

312 Farmington Avenue

Farmington, Connecticut, 06032,

United States

860-676-8654

Want to inform investors similar to Horizon Technology Finance about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Horizon Technology Finance News

Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update

Jan 11, 2023

01/11/2023 | 04:16pm EST Message : *Required fields - Horizon Platform Originates $114 Million of New Loans in Q4, Including $104 Million of New Loans for HRZN - - HRZN Grows Loan Portfolio by $262 Million in 2022 - - Horizon Platform Ends 2022 with Committed Backlog of $255 Million, Including $220 Million in HRZN Commitments -    FARMINGTON, Conn., Jan. 11, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the fourth quarter ended December 31, 2022 and an update on the lending platform ("Horizon Platform") of Horizon Technology Finance Management LLC ("HTFM"), its investment adviser. "The Horizon Platform ended the year with another quarter of strong originations and portfolio growth, funding $114 million of loans, including $104 million of loans for HRZN," said Gerald A. Michaud, President of HRZN and HTFM. "The power of the Horizon brand was evident throughout 2022, as the Horizon Platform originated over $543 million in new loans, including a record-high $403 million for the HRZN portfolio." "Additionally, the Horizon Platform's committed backlog of debt investments remained strong at $255 million, including $220 million in HRZN commitments, and the Horizon Platform pipeline remains robust, providing ample runway to thoughtfully grow HRZN's portfolio of debt investments," added Mr. Michaud. "As we enter 2023, we believe the Horizon Platform and HRZN remain well positioned to deliver additional value to HRZN's shareholders." Fourth Quarter 2022 Portfolio Update Originations During the fourth quarter of 2022, a total of $113.5 million of loans funded through the Horizon Platform, including ten loans totaling $103.9 million funded by HRZN as follows: $45.0 million to a new portfolio company, Evelo Biosciences, Inc. (NASDAQ: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis. $10.6 million to a new portfolio company, an online interior design service, a portion of which was used to purchase assets of an existing portfolio company of HRZN which resulted in a partial paydown of HRZN's debt investment in such existing portfolio company. $10.0 million to a new portfolio company, Groundspeed Analytics, Inc., a developer of an AI platform that captures, structures, and delivers complete risk data to commercial P&C insurance carriers. $10.0 million to an existing portfolio company, Magnolia Medical Technologies, Inc., a developer of an FDA-cleared high-precision blood culture collection medical device. $7.5 million to an existing portfolio company, Divergent Technologies, Inc., a creator of an innovative global manufacturing infrastructure platform for the automotive industry. $7.5 million to an existing portfolio company, Soli Organic Inc., a leading grower and marketer of fresh organic culinary herbs, providing sustainable, USDA-certified organic, regionally grown produce to retailers. $7.0 million to a new portfolio company, Robin Healthcare, Inc., a developer of an AI device that silently observes healthcare visits, extracts data, then builds and uploads clinical notes to a patient's electronic health record. $2.5 million to an existing portfolio company, Sonex Health, Inc., a developer of technology, education and training programs for ultrasound guided procedures. $2.5 million to an existing portfolio company, a developer of next generation microbial solutions for both companion and livestock animals. $1.3 million to an existing portfolio company, a data platform that enables marketers to build personalized digital experiences and 1-to-1 marketing campaigns by focusing on behavioral data. Liquidity Events and Partial Paydowns HRZN experienced liquidity or partial paydown events from two portfolio companies in the fourth quarter of 2022, including principal prepayments of $8.2 million, compared to $22.0 million of principal prepayments during the third quarter of 2022:  In November, LogicBio Therapeutics, Inc. prepaid its outstanding principal balance of $2.6 million on its venture loan, plus interest, end-of-term payment and prepayment fee. HRZN continues to hold warrants in the company. In December, HRZN received a paydown of $5.6 million on its venture loan to Interior Define, Inc. from the sale of certain assets of Interior Define, Inc. to a new borrower of HRZN, whose purchase of such assets was financed by HRZN with a new debt investment. Principal Payments Received During the fourth quarter of 2022, HRZN received regularly scheduled principal payments on investments totaling $4.1 million, compared to regularly scheduled principal payments totaling $4.5 million during the third quarter of 2022. Commitments During the quarter ended December 31, 2022, HRZN closed new loan commitments totaling $102.6 million to five companies, compared to new loan commitments of $156.0 million to eight companies in the third quarter of 2022. Across the Horizon Platform, an additional $3.4 million of unfunded loan commitments were closed. Pipeline and Term Sheets As of December 31, 2022, HRZN's unfunded loan approvals and commitments ("Committed Backlog") were $220.0 million to 18 companies. This compares to a Committed Backlog of $252.0 million to 26 companies at HRZN as of September 30, 2022. HRZN's portfolio companies have discretion whether to draw down such commitments and the right of a portfolio company to draw down its commitment is often subject to achievement of specific milestones and other conditions to borrowing. Accordingly, there is no assurance that any or all of these transactions will be funded by HRZN. Across the Horizon Platform, the quarter ended with an additional $35.0 million of unfunded loan approvals and commitments. During the quarter, HTFM received signed term sheets that are in the approval process, which may result in the Horizon Platform providing up to an aggregate of $30.0 million of new debt investments. These opportunities are subject to underwriting conditions including, but not limited to, the completion of due diligence, negotiation of definitive documentation and investment committee approval, as well as compliance with HTFM's allocation policy. Accordingly, there is no assurance that any or all of these transactions will be completed or funded by HRZN. Warrant and Equity Portfolio As of December 31, 2022, HRZN held a portfolio of warrant and equity positions in 99 portfolio companies, including 82 private companies, which provides the potential for future additional returns to HRZN's shareholders. About Horizon Technology Finance Horizon Technology Finance Corporation (NASDAQ: HRZN) is a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio's return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located in Austin, Texas, Chicago, Illinois, Reston, Virginia and Portland, Maine. To learn more, please visit horizontechfinance.com . Forward-Looking Statements Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Horizon's filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Contacts:

Horizon Technology Finance Investments

124 Investments

Horizon Technology Finance has made 124 investments. Their latest investment was in Slingshot Aerospace as part of their Loan on December 12, 2022.

CBI Logo

Horizon Technology Finance Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/6/2022

Loan

Slingshot Aerospace

Yes

1

11/29/2022

Line of Credit

Groundspeed Analytics

Yes

3

10/24/2022

Loan

Robin Healthcare

$17M

Yes

3

10/11/2022

Line of Credit

Subscribe to see more

$99M

Subscribe to see more

10

7/13/2022

Loan - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/6/2022

11/29/2022

10/24/2022

10/11/2022

7/13/2022

Round

Loan

Line of Credit

Loan

Line of Credit

Loan - II

Company

Slingshot Aerospace

Groundspeed Analytics

Robin Healthcare

Subscribe to see more

Subscribe to see more

Amount

$17M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

3

3

10

10

Horizon Technology Finance Portfolio Exits

50 Portfolio Exits

Horizon Technology Finance has 50 portfolio exits. Their latest portfolio exit was Embody on January 05, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/5/2023

Acquired

$99M

18

12/9/2022

Reverse Merger

$99M

8

8/30/2022

Reverse Merger

$99M

3

8/1/2022

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

7/26/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/5/2023

12/9/2022

8/30/2022

8/1/2022

7/26/2022

Exit

Acquired

Reverse Merger

Reverse Merger

Acq - Pending

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

18

8

3

10

10

Horizon Technology Finance Partners & Customers

2 Partners and customers

Horizon Technology Finance has 2 strategic partners and customers. Horizon Technology Finance recently partnered with Titan Pharmaceuticals on February 2, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

2/1/2018

Client

United States

Titan Pharmaceuticals Reports First Quarter 2018 Financial Results

`` We believe that entering into our strategic partnership with Molteni marked a potential important inflection point for both Probuphine and Titan Pharmaceuticals , Inc. , '' said Titan Pharmaceuticals , Inc. 's President and CEO , Sunil Bhonsle .

1

6/29/2012

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

2/1/2018

6/29/2012

Type

Client

Partner

Business Partner

Country

United States

United States

News Snippet

Titan Pharmaceuticals Reports First Quarter 2018 Financial Results

`` We believe that entering into our strategic partnership with Molteni marked a potential important inflection point for both Probuphine and Titan Pharmaceuticals , Inc. , '' said Titan Pharmaceuticals , Inc. 's President and CEO , Sunil Bhonsle .

Subscribe to see more

Subscribe to see more

Sources

1

10

Horizon Technology Finance Service Providers

1 Service Provider

Horizon Technology Finance has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Horizon Technology Finance Team

7 Team Members

Horizon Technology Finance has 7 team members, including current Chief Financial Officer, Senior Vice President, Dan Trolio.

Name

Work History

Title

Status

Dan Trolio

Chief Financial Officer, Senior Vice President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Dan Trolio

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Financial Officer, Senior Vice President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.